Combination therapy for effecting weight loss and treating obesity

Patent 7056890 Issued on June 6, 2006. Estimated Expiration Date:

June 3, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Anticonvulsant sulfamate derivatives
Patent #: 4513006
Issued on: 04/23/1985
Inventor: Maryanoff , et al.

Anticonvulsant phenethyl sulfamates
Patent #: 4792569
Issued on: 12/20/1988
Inventor: Maryanoff , et al.

Method of assisting weight loss
Patent #: 4895845
Issued on: 01/23/1990
Inventor: Seed

Anticonvulsant fructopyranose cyclic sulfites and sulfates
Patent #: 5242942
Issued on: 09/07/1993
Inventor: Costanzo, et al.

Ethanolamine benzoate compounds
Patent #: 5266591
Issued on: 11/30/1993
Inventor: Wierzbicki, et al.

Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
Patent #: 5273993
Issued on: 12/28/1993
Inventor: Lo, et al.

Anticonvulsant pseudofructopyranose sulfamates
Patent #: 5498629
Issued on: 03/12/1996
Inventor: Costenzo, et al.

Composition and method for weight reduction and long term management of obesity
Patent #: 5543405
Issued on: 08/06/1996
Inventor: Keown, et al.

Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
Patent #: 5753693
Issued on: 05/19/1998
Inventor: Shank

Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
Patent #: 5753694
Issued on: 05/19/1998
Inventor: Shank

More ...

Inventor

Najarian, Thomas

Assignee

VIVUS, Inc.

Application

No. 10454368 filed on 06/03/2003

US Classes:

514/23, Carbohydrate (i.e., saccharide radical containing) DOAI514/646, Benzene ring containing558/48, Nitrogen attached directly or indirectly to the sulfonate group by acyclic nonionic bonding514/439, Plural hetero atoms in the hetero ring514/539, Plural separated benzene rings in Z moiety514/400, At imidazole ring carbon514/188, Hetero ring is six-membered consisting of one nitrogen and five carbons514/454, Tricyclo ring system having the hetero ring as one of the cyclos514/455, Chalcogen bonded directly to ring carbon of the hetero ring514/651, Ether oxygen is part of the chain514/280, Pentacyclo ring system having the six-membered hetero ring as one of the cyclos424/464Tablets, lozenges, or pills

Examiners

Primary: Maier, Leigh C.

Attorney, Agent or Firm

Foreign Patent References

WO 00/50020 WO 08/01/2000
WO 00/76493 WO 12/01/2000

International Classes

A61K 31/135
A61K 31/70

Abstract

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

Other References

Physicians' Desk Reference (1995) entry for “phentermine hydrochloride” pp. 2508-2509.
Carek, P. et al “Current concepts in the pharmacological management of obesity” Drugs (1999) vol 6, pp. 883-904.
Griffen, L. et al “The ‘phen-pro’ diet drug combination . . . ” Arch. Intern. Med. (1998) vol. 158, pp. 1278-1279.
Weintraub, M. et al “A double-blind clinical trial in weight control” Arch. Intern. Med. (1984) vol. 144, pp. 1143-1148.
U.S. Appl. No. 60/139,022, filed Dec. 21, 2000, Najarian.
U.S. Appl. No. 60/178,563, filed Dec. 21, 2000, Najarian.
U.S. Appl. No. 60/181,265, filed Dec. 21, 2000, Najarian.
Physician's Desk Reference, 49^th Edition, pp. 2508-2509 (1995).
Bradley et al. (1999), “Bupropion SR with Phentermine for Weight Reduction,” Books of Abstracts, American Psychiactric Association Meeting (distributed to meeting attendees), Washington, D.C. (abstract only).
Bray et al (2002), “Topiramate Produces Dose -Related Weight Loss,” 62^ndAnnual American Diabetes Association Meeting, San Francisco.
Coyne (1997), letter regarding Ionamin to the U.S. Food and Drug Administration, printed from http://www.fda.gov/medwatch/safety/1997)/ionami2.htm. Sep. 1997.
FDC Reports, Inc. (1999), “Appetite Suppression Drug Excluded by 81% of Employers - PBMI Survey,” The Green Sheet 48(19):3.
Gadde et al. (1999), “Bupropion SR in Obesity: A Rendomized Double-Blinded Placebo-Controlled Study,” Obesity Research 7(Suppl. 1):51F, Abstract 0136; Annual Meeting of the North American Association for the Study of Obesity, Charlestown, S.C.
Michelucci et al., (1998), “The Preclinical and Therapeutic Activity of the Novel Anticonvulsant Topiramte,” CNS Drug Reviews 4(2):165-186.
Penovich et al. (1994), “Weight Loss in Patients Receiving Topiramate for Intractable Epilepsy,” Neurology 44(Suppl. 2), Abstract 309P, 46^th Annual Meeting of the American Academy of Neurology, Washington, D.C.
Planet Rx, Inc. (1999), “Drug Therapies”, Fastin, Ionamin (Phentermine), pp. 3-4, printed from http://www.obesity.com.
Potter et al., (1997), “Sustained Weight Loss Associated with 12-Month Topiramate Therapy,” Epilepsia 38(Suppl.8):97; Annual Meeting of the American Epilepsy Society, Boston MA.
Raritan (2002), “Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability,” Johnson & Johnson Pharmaceutical Research & Development, LLC press release, printed from http://www.jnj.com/news finance/448.htm. Feb. 2002.
U.S. Food and Drug Administration (1997) “FASTIN (Phentermine HCI) Capsules,” Oct. 1997 Drug Labeling Changes, printed from http://www.fda.gov/medwatch/safety/1997/oct97.htm.
U.S. Food and Drug Administration (1999), “IONAMINE (Phentermine Resin) Capsules,” Feb. 1998 Drug Labeling Changes, printed from http://www.fda.gov/medwatch/safety/1998.feb99.htm.
Zarate (2000), “Antipsychotic Drug Side Effect Issues in Bipolar Manic Patients,” J. Clin. Psychiatry 61(Suppl. 8):52-61, Derwent.